FDA's New Rules for Cheaper Copycat Drugs: Biosimilars Get a Guidance Boost
Published Date: 9/9/2025
Notice
Summary
The FDA just released final advice to help drug makers prove their new protein medicines are just as good as the originals. This update affects companies developing biosimilars by clarifying how to compare products and what info to include in their applications. It aims to speed up approval and save money by making the process clearer and more reliable.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Clarifies how to show biosimilarity
The FDA released final guidance explaining how drug makers should design and evaluate comparative analytical studies to show a therapeutic protein is biosimilar to a reference product licensed under the Public Health Service Act. The guidance finalizes and replaces the draft guidance issued May 22, 2019 and the prior final guidance issued April 30, 2015.
Specifies CMC info for biosimilar applications
The final guidance provides recommendations to sponsors on the scientific and technical information to include in the chemistry, manufacturing, and controls (CMC) section of a marketing application submitted under the Public Health Service Act. Sponsors developing therapeutic protein biosimilars should follow these CMC recommendations when preparing their applications.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20503, Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction
The FDA fixed a previous announcement about Oxandrin tablets (2.5 mg and 10 mg) being pulled from the market due to safety or effectiveness concerns. This update confirms that not only the original drug but also several generic versions were withdrawn and removed from the official drug list. Patients, doctors, and drug makers should note these changes, which affect availability and prescribing options immediately.
Previous / Next Documents
Previous: 2025-17222, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Tobacco Product Establishment Registration and Listing
The FDA wants to keep track of tobacco product makers by updating their registration and listing rules. This affects businesses that make or sell tobacco products, who’ll need to share info with the FDA. The government is checking the paperwork to make sure it’s fair and won’t cost too much time or money.
Next: 2025-17228, Cheniere Corpus Christi Pipeline, LP; Notice of Request for Extension of Time
Cheniere Corpus Christi Pipeline, LP is asking for more time—until the end of 2029—to finish building their Stage 3 Pipeline Project in Texas. This project includes a big pipeline and some powerful compressor machines to help move gas. The delay means they need extra time to complete important parts, but they’ve already started and even put some equipment to work.